The company is not selling any shares of its common stock under this prospectus and will not receive any of the proceeds from the sale of the ...

In doing so, neuro-symbolic AI stands poised to reshape how we build and integrate AI and our businesses as a whole—ushering in a new era of technology in the upcoming decade that feels both deeply ...

A digital therapeutic software company has announced a £10.35m Series A funding round, led by investor IW Capital.

Alzamend Neuro , Inc. (NASDAQ ... for an equal number of Series C Convertible Preferred Stock, along with the sale of up to 500 shares of Series C Preferred Stock and corresponding warrants ...

Alzamend Neuro , Inc. (NASDAQ:ALZN), a biopharmaceutical company specializing ... Stock for an equal number of Series C Convertible Preferred Stock, along with the sale of up to 500 shares of Series C ...

At the end of February, its value increased by 57% compared to the same period last year, further tempting those who exploit ...

ClearPoint's Q4 updates: neurosurgery growth, expanding services, controlled cash burn and high-potential partner programs driving future prospects. See more here.

In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

increasing hospital throughput and driving sales and scale in our existing accounts. We will train sites on the use of the ClearPoint Neuro technology in both the MRI Suite and the OR to build ...

ClearPoint Neuro Inc (CLPT) reports a 31% revenue increase, enhanced gross margins, and strategic global expansions, despite facing operational challenges.